

2023 年

英文

Kaneyasu H, Takahashi K, Ohta N, Okada S, Kimura S, Yasuno S, Murata S, Katsura S, Yamada N, Shiraishi K, Tsuda J, Miyai S, Kurahashi H, Hasegawa S, Shimomura Y. Novel compound heterozygous mutations in the PLEC gene in a neonate with epidermolysis bullosa simplex with pyloric atresia. *Journal of dermatology*. 2023; 50(2):239-244.

Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes. *BJUI Compass*. 2023; 4(3):305-313.

Grivas P, Kopyltsov E, Su PJ, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C, Climent Duran MA, Bamias A, Caserta C, Chang J, Cislo P, di Pietro A, Wang J, Powles T. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. *European Urology*. 2023; 83(4):320-328.

Shiota M, Inoue R, Tashiro K, Kobayashi K, Horiyama S, Kanji H, Eto M, Egawa S, Haginaka J, Matsuyama H. A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer. *The Journal of Clinical Pharmacology*. 2023; 63(4):445-454.

Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M. Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study. *Endocrine-Related Cancer*. 2023; 30(7):e230044.

Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H,

Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNIp-RCC investigators. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNIp-RCC trial.

Cancer Immunology, Immunotherapy. 2023; 72(6):1903-1915.

Miyamoto T, Miyake M, Nakahama T, Nishimura N, Onishi K, Iida K, Yonemori M, Enokida H, Nakagawa M, Matsumoto H, Matsuyama H, Matsushita Y, Miyake H, Fujii T, Shimada K, Baba S, Kinjo M, Shimokama T, Okumura K, Fujimoto K; Nishinohon Uro-oncology Extensive Collaboration group. Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.

International Journal of Urology. 2023; 30(5):473-481.

Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.

European Urology. 2023; 84(1):95-108.

Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNIp-RCC Investigators. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNIp-RCC study.

International Journal of Urology. 2023; 30(9):788-796.

Nishiyama H, Tsuzuki T, Ohyama C, Matsuyama H, Shinozaki K, Hayashi Y, Hayashi N, Koto R, Shin E, Ogawa O. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.

International Journal of Clinical Oncology. 2023 Oct;28(10):1398-1410.

Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H,

Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H, Fujimoto K; Nishinohon Uro-oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines. BJUI Compass. 2023; 5(2):269-280.

Nishimura N, Miyake M, Nakahama T, Miyamoto T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study. International Journal of Urology. 2023; 30(12):1112-1119.

和文

太田 伸男, 竹野 幸夫, 竹内 万彦, 大原 浩達, 沖中 洋介, 上條 篤, 児玉 悟, 洲崎 勲夫, 常見 泰弘, 戸嶋 一郎, 仲野 敦子, 西田 直哉, 増田 佐和子, 森 恵莉, 坂井田 寛, 森本 耕三, 慶長 直人, 後藤 慎平, 近藤 光子, 阿保 未来, 金子 猛, 肥沼 悟郎, 錦戸 知喜, 長尾 みづほ, 中谷 中, 伊達 洋至, 白石 晃司, 藤枝 重治, 貝沼 圭吾, 線毛機能不全症候群の診療の手引き作成委員会. 線毛機能不全症候群の診療の手引き.

日本鼻科学会雑誌. 2023;62(1)1-108.

竹島 徹平, 安東 聡, 岩端 威之, 梅本 幸裕, 加藤 繭子, 小林 秀行, 小宮 顕, 白石 晃司, 谷口 久哲, 千葉 公嗣, 辻村 晃, 福原 慎一郎, 湯村 寧. 令和 4 年 4 月からの不妊治療保険適用化に伴う保険医療機関における男性不妊診療の変化 生殖医学会男性不妊 Special Interest Group(SIG) アンケートより.

日本泌尿器科学会雑誌. 2023; 114(3): 75-80.